Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
Not intended for US and UK audiences BI 765423 has been developed…
Boehringer Ingelheim announces appointment to Board of Managing Directors
Harsha Deshmukh has been appointed a member of the Board of Managing…
